- Home
- TMO vs GILD Comparison
TMO vs GILD Comparison
Compare TMO & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMO | GILD |
|---|---|---|
| Founded | 1956 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.3B | 168.6B |
| IPO Year | 1996 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TMO | GILD |
|---|---|---|
| Price | $453.51 | $133.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | ★ $636.00 | $148.39 |
| AVG Volume (30 Days) | 2.2M | ★ 5.0M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | 0.40% | ★ 2.55% |
| EPS Growth | 7.32 | ★ 1684.21 |
| EPS | ★ 4.43 | 1.61 |
| Revenue | $20,918,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $6.55 | $4.68 |
| Revenue Next Year | $5.11 | $6.04 |
| P/E Ratio | $101.26 | ★ $83.56 |
| Revenue Growth | ★ 14.47 | 9.98 |
| 52 Week Low | $385.46 | $105.69 |
| 52 Week High | $643.99 | $157.29 |
Technical Indicators
Market Signals| Indicator | TMO | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 51.20 |
| Support Level | $435.27 | $128.33 |
| Resistance Level | $502.20 | $137.50 |
| Average True Range (ATR) | 12.35 | 3.23 |
| MACD | 1.12 | 0.49 |
| Stochastic Oscillator | 41.17 | 58.95 |
Price Performance
Historical ComparisonAbout TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).